The hERG potassium channel as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 3, 2007, Pages 321-336

  Witchel, Harry J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Arrhythmia; Dysrhythmia; hERG; K+ channel; Kv 11.1; KCNH2; Torsades de pointes

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; AMIODARONE; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DOFETILIDE; DRONEDARONE; MALLOTOXIN; MOXIFLOXACIN; NS 1643; NS 3623; PD 118057; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL STIMULATING AGENT; PROTEIN SUBUNIT; RPR 260243; SOTALOL; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL SELECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; GENE TARGETING; GENE THERAPY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HUMAN; LEUKEMIA; LONG QT SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MODEL; MUSCLE ATROPHY; PATHOGENESIS; PHARMACOPHORE; POTASSIUM CONDUCTANCE; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK REDUCTION; SEQUENCE ANALYSIS; SHORT QT SYNDROME; STRUCTURE ANALYSIS; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNEL BLOCKERS; RISK FACTORS;

EID: 33847139443     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.3.321     Document Type: Review

References (145)

1. GUTMAN GA, CHANDY KG, GRISSMER S et al.: International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. (2005) 57(4):473-508.
2. WARMKE JW, GANETZKY B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Sci. USA (1994) 91:3438-3442.
3. Kr potassium channel. Cell (1995) 81(2):299-307.
4. TRUDEAU MC, WARMKE JW, GANETZKY B, ROBERTSON GA: HERG, a human inward rectifier in the voltage gated potassium channel family. Science (1995) 269:92-95.
5. KEATING MT, SANGUINETTI MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell (2001) 104(4):569-580.
6. SANGUINETTI MC, TRISTANI-FIROUZI M: hERG potassium channels and cardiac arrhythmia. Nature (2006) 440(7083):463-469.
7. WITCHEL HJ, HANCOX JC: Familial and acquired Long QT Syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharm. Physiol. (2000) 27(10):753-766.
8. CURRAN ME, SPLAWSKI I, TIMOTHY KW et al.: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell (1995) 80:795-803.
9. HONDEGHEM LM: Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J. Cardiovasc. Electrophysiol. (2006) 17(3):337-340.
10. HONDEGHEM LM, CARLSSON L, DUKER G: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 103(15):2004-2013.
11. WITCHEL HJ, HANCOX JC, NUTT DJ: Psychotropic drugs, cardiac arrhythmia, and sudden death. J. Clin. Psychopharmacol. (2003) 23(1):58-77.
12. LOWN B: Sudden cardiac death: biobehavioral perspective. Circulation (1987) 76(1 Pt. 2):I186-I196.
13. SANGUINETTI MC, KEATING MT: Role of delayed rectifier potassium channels in cardiac repolarization and arrhythmias. News Physiol. Sci. (1997) 12:152-157.
14. SCHWARTZ PJ, PERITI M, MALLIANI A: The long Q-T syndrome. Am. Heart J. (1975) 89(3):378-390.
15. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. (1990) 96(1):195-215.
16. + channel. Open-channel block by methanesulfonanilides. Circ. Res. (1996) 78:499-503.
17. SNYDERS DJ, CHAUDHARY A: High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol. Pharm. (1996) 49:949-955.
18. LOMBARDI F, TERRANOVA P: Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. Curr. Med. Chem. (2006) 13(14):1635-1653.
19. CRUMB W, CAVERO I: QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm. Sci. Technol. Today (1999) 2(7):270-280.
20. REDFERN WS, CARLSSON L, DAVIS AS et al.: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. (2003) 58(1):32-45.
21. ZHOU Z, GONG Q, YE B et al.: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. (1998) 74:230-241.
22. HANCOX JC, LEVI AJ, WITCHEL HJ: Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential. Pflügers Arch. (1998) 436:843-853.
23. + channel. Nature (2003) 423(6935):33-41.
24. MORAIS CABRAL JH, LEE A, COHEN SL et al.: Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell (1998) 95:649-655.
25. SMITH PL, BAUKROWITZ T, YELLEN G: The inward rectification mechanism of the HERG cardiac potassium channel. Nature (1996) 379:833-836.
26. AKHAVAN A, ATANASIU R, NOGUCHI T et al.: Identification of the cyclic-nucleotide-binding domain as a conserved determinant of ion-channel cell-surface localization. J. Cell Sci. (2005) 118(Pt. 13):2803-2812.
27. + channel by dual pathways. Curr. Biol. (2000) 10(11):671-674.
28. + channels. Pflügers Arch. (2002) 445(3):423-430.
29. MACKINNON R: Determination of the subunit stoichiometry of a voltage-activated potassium channel. Nature (1991) 350(6315):232-235.
30. + current. Circ. Res. (1997) 81:870-878.
31. + channel in mouse and human hearts. Circ. Res. (1997) 81:719-726.
32. Kr channels minimally comprise of HERG 1a and HERG 1b channels. J. Biol. Chem. (2004) 279(43):44690-44694.
33. + channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current. J. Biol. Chem. (1998) 273:27231-27235.
34. SHI W, WYMORE RS, WANG H-S et al.: Identification of two nervous system-specific members of the erg potassium channel gene family. J. Neurosci. (1997) 17(24):9423-9432.
35. Kr. Nature (1997) 388:289-292.
36. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 97:175-187.
37. SESTI F, ABBOTT GW, WEI J et al.: A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. USA (2000) 97(19):10613-10618.
38. v4.2 and modulates its gating function: potential role as β subunit of cardiac transient outward channel? Circ. Res. (2001) 88(10):1012-1019.
39. ABBOTT GW, GOLDSTEIN SA: Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism. FASEB J. (2002) 16(3):390-400.
40. WEERAPURA M, NATTEL S, CHARTIER D, CABALLERO R, HEBERT TE: A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J. Physiol. (2002) 540(Pt. 1):15-27.
41. + channel. Science (2005) 309(5736):897-903.
42. + channels: friend and foe. Trends Pharmacol. Sci. (2001) 22(5):240-246.
43. MITCHESON JS, CHEN J, SANGUINETTI MC: Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. (2000) 115(3):229-240.
44. MITCHESON JS, PERRY MD: Molecular determinants of high-affinity drug binding to HERG channels. Curr. Opin. Drug Discov. Devel. (2003) 6(5):667-674.
45. MITCHESON JS, CHEN J, LIN M, CULBERSON C, SANGUINETTI MC: A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA (2000) 97(22):12329-12333.
46. WITCHEL HJ, DEMPSEY CE, SESSIONS RB et al.: The low potency, voltage-dependent HERG blocker propafenone - molecular determinants and drug trapping. Mol. Pharmacol. (2004) 66(5):1201-1212.
47. FERNANDEZ D, GHANTA A, KAUFFMAN GW, SANGUINETTI MC: Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. (2004) 279(11):10120-10127.
48. + channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. J. Physiol. (London) (1998) 509(Pt. 1):129-137.
49. HANCOX JC, WITCHEL HJ, VARGHESE A: Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation. Biochem. Biophys. Res. Commun. (1998) 253(3):719-724.
50. LEES-MILLER JP, DUAN Y, TENG GQ, DUFF HJ: Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. (2000) 57(2):367-374.
51. PAUL A, WITCHEL HJ, HANCOX JC: Inhibition of HERG potassium channel current by the class la antiarrhythmic agent disopyramide. Biochem. Biophys. Res. Commun. (2001) 280:1243-1250.
52. + channels. Mol. Pharmacol. (2001) 60(6):1343-1348.
53. CHEN J, SEEBOHM G, SANGUINETTI MC: Position of aromaric residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci. USA (2002) 99(19):12461-12466.
54. LAFUENTE-LAFUENTE C, MOULY S, LONGAS-TEJERO MA, MAHE I, BERGMANN JF: Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch. Intern. Med. (2006) 166(7):719-728.
55. CAMM J: Medical management of atrial fibrillation: state of the art. J. Cardiovasc. Electrophysiol. (2006) 17(Suppl. 2):S2-S6.
56. WYSE DG, WALDO AL, DIMARCO JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347(23):1825-1833.
57. Committee for Proprietary Medicinal Products: Points to consider: the assessment for the potential for QT prolongation by non-cardiovascular medicinal products (1997); Report #CPMP/986/96, European Agency for the Evaluation of Medicinal Products, London, UK.
58. ICH (Expert Working Group (safety) of the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use): S7A Safety Pharmacology Studies for Human Pharmaceuticals: Guidance for Industry (2001). FDA: Rockville, Maryland, USA.
59. BEDNAR MM, HARRIGAN EP, RUSKIN JN: Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am. J. Cardiol. (2002) 89(11):1316-1319.
60. MAKKAR RR, FROMM BS, STEINMAN RT, MEISSNER MD, LEHMANN MH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 270(21):2590-2597.
61. ICH (Expert Working Group (safety) of the international conference on harmonisation of technical requirements for Registration of pharmaceuticals for human use): The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals, S7B (2005). FDA: Rockville, Maryland, USA.
62. WITCHEL HJ, MILNES JT, MITCHESON JS, HANCOX JC: Troubleshooting a heterologous potassium channel current used for in vitro screening for QT interval prolongation: HERG, mammalian cell lines and Xenopus oocytes. J. Pharmacol. Toxicol. Methods (2003) 48:65-80.
63. KIRSCH GE, TREPAKOVA ES, BRIMECOMBE JC et al.: Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods (2004) 50(2):93-101.
64. 3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur. J Pharmacol. (2001) 430(1):147-148.
65. + channels. J. Pharmacol. Sci. (2004) 95(3):311-319.
66. WANG J, DELLA PK, WANG H et al.: Functional and Pharmacological properties of canine ERG potassium channels. Am. J Physiol Heart Circ. Physiol (2003) 284(1):H256-H267.
67. ZHOU Z, VORPERIAN VR, GONG Q, ZHANG S, JANUARY CT: Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol. (1999) 10(6):836-843.
68. KAMIYA K, NIWA R, MITCHESON JS, SANGUINETTI MC: Molecular determinants of HERG channel block. Mol. Pharmacol. (2006) 69(5):1709-1716.
69. WEBSTER R, LEISHMAN D, WALKER D: Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Devel. (2002) 5(1):116-126.
70. 125I]-BeKm-1. Pflügers Arch. (2003) 447(1):55-63.
71. ZHANG M, KOROLKOVA YV,, LIU J et al.: BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys. J. (2003) 84(5):3022-3036.
72. TANG W, KANG J, WU X et al.: Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen. (2001) 6(5):325-331.
73. SOROTA S, ZHANG XS, MARGULIS M, TUCKER K, PRIESTLEY T: Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay. Drug Dev. Technol. (2005)3(1):47-57.
74. NETZER R, EBNETH A, BISCHOFF U, PONGS O: Screening lead compounds for QT interval prolongation. Drug Discov. Today. (2001) 6(2):78-84.
75. DUBIN AE, NASSER N, ROHRBACHER J et al.: Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J. Biomol. Screen. (2005) 10(2):168-181.
76. KISS L, BENNETT PB, UEBELE VN et al.: High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay. Drug Dev. Technol. (2003) 1(1 Pt. 2):127-135.
77. FINKEL A, WITTEL A, YANG N et al.: Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J. Biomol. Screen. (2006) 11(5):488-496.
78. GUSSAK I, BRUGADA P, BRUGADA J et al.: Idiopathic short QT interval: a new clinical syndrome? Cardiology (2000) 94(2):99-102.
79. BJERREGAARD P, JAHANGIR A, GUSSAK I: Targeted therapy for short QT syndrome. Expert Opin. Ther. Targets (2006) 10(3):393-400.
80. GAITA F, GIUSTETTO C, BIANCHI F et al.: Short QT Syndrome: a familial cause of sudden death. Circulation (2003) 108(8):965-970.
81. BRUGADA R, HONG K, DUMAINE R et al.: Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2004) 109(1):30-35.
82. MCPATE MJ, WITCHEL HJ, HANCOX JC: Short QT syndrome. Fut. Cardiol. (2006)2(3):293-301.
83. + channels. J. Physiol. (2006) 573(Pt. 2):291-304.
84. HONG K, BJERREGAARD P, GUSSAK I, BRUGADA R: Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol. (2005) 16(4):394-396.
85. Kr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc. Res. (2005) 67(3):498-509.
86. + channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 C. Biochem. Biophys. Res. Commun. (2005) 334(2):441-449.
87. SCHIMPF R, WOLPERT C, BIANCHI F et al.: Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc. Electrophysiol. (2003) 14(12):1273-1277.
88. GAITA F, GIUSTETTO C, BIANCHI F et al.: Short QT syndrome: pharmacological treatment. J. Am. Coll. Cardiol. (2004) 43(8):1494-1499.
89. MILNES JT, CROCIANI O, ARCANGELI A, HANCOX JC, WITCHEL HJ: Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. (2003) 139(5):887-898.
90. MCPATE MJ, DUNCAN RS, WITCHEL HJ, HANCOX JC: Disopyramide is an effective inhibitor of mutant HERG K(+) channels involved in variant 1 short QT syndrome. J. Mol. Cell Cardiol. (2006) 41(3):563-566.
91. GUSSAK I, BJERREGAARD P: Short QT syndrome - 5 years of progress. J. Electrocardiol. (2005) 38(4):375-377.
92. ARCANGELI A: Expression and role of hERG channels in cancer cells. Novartis Found. Symp. (2005) 266:225-232.
93. CHERUBINI A, TADDEI GL, CROCIANI O et al.: HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br. J. Cancer (2000) 83(12):1722-1729.
94. LASTRAIOLI E, GUASTI L, CROCIANI O et al.: herg1 gene and herg1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. (2004) 64(2):606-611.
95. 3 integrin in the preosteoclastic leukemia cell line FLG 29.1. J. Biol. Chem. (2001) 276(7):4923-4931.
96. PILLOZZI S, BRIZZI MF, BALZI M et al.: HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia (2002) 16(9):1791-1798.
97. + channels in neoplastic hematopoietic cells. J. Biol. Chem. (2002) 277(21):18528-18534.
98. + current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. (1998) 58(4):815-822.
99. CROCIANI O, GUASTI L, BALZI M et al.: Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J. Biol. Chem. (2003) 278(5):2947-2955.
100. 3 integrin in the preosteoclastic leukemia cell line FLG 29.1. J. Biol. Chem. (2001) 276(7):4923-4931.
101. MASI A, BECCHETTI A, RESTANO-CASSULINI R et al.: hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br. J. Cancer (2005) 93(7):781-792.
102. GLASS DJ: Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. (2003) 5(2):87-90.
103. + channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway. FASEB J. (2006) 20(9):1531-1533.
104. ECHT DS, LIEBSON PR, MITCHELL LB et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. (1991) 324(12):781-788.
105. COLATSKY TJ, FOLLMER CH, STARMER CF: Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation (1990) 72:1092-1103.
106. ANDERSON JL, PRYSTOWSKY EN: Sotalol: An important new antiarrhythmic. Am. Heart J. (1999) 137(3):388-409.
107. SINGH BN: Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents. Am. J. Cardiol. (1993) 72(4):8A-18A.
108. WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet (1996) 348(9019):7-12.
109. PERRY M, DE GROOT MJ, HELLIWELL R et al.: Structural determinants of HERG channel block by clofilium and ibutilide. Mol. Pharmacol. (2004) 66(5):240-249.
110. MILNES JT, DEMPSEY CE, RIDLEY JM et al.: Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett. (2003) 547(1-3):20-26.
111. TESCHEMACHER AG, SEWARD EP, HANCOX JC, WITCHEL HJ: Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br. J. Pharmacol. (1999) 128(2):479-485.
112. + channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem. Biophys. Res. Commun. (2004) 325(3):883-891.
113. + channel. Mol. Pharmacol. (2005) 67(3):827-836.
114. HANSEN RS, DINESS TG, CHRIST T et al.: Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-pheny l)-urea (NS 1643). Mol. Pharmacol. (2006) 69(1):266-277.
115. HANSEN RS, DINESS TG, CHRIST T et al.: Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)- N′-(3′-trifluoromethylphenyl)urea]. Mol. Pharmacol. (2006) 70:1319-1329.
116. ZHOU J, AUGELLI-SZAFRAN CE, BRADLEY JA et al.: Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. (2005) 68:876-884.
117. ZENG H, LOZINSKAYA IM, LIN Z et al.: Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J. Pharmacol. Exp. Ther. (2006) 319(2):957-962.
118. CASIS O, OLESEN SP, SANGUINETTI MC: Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol. Pharmacol. (2006) 69(2):658-665.
119. THOMAS D, ZHANG W, KARLE CA et al.: Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J. Biol. Chem. (1999) 274(39):27457-27462.
120. KIEHN J, KARLE C, THOMAS D et al.: HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J. Biol. Chem. (1998) 273(39):25285-25291.
121. THOMAS D, ZHANG W, WU K et al.: Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. Cardiovasc. Res. (2003) 59(1):14-26.
122. ZHOU Z, GONG Q, JANUARY CT: Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J. Biol. Chem. (1999)274(44):31123-31126.
123. FICKER E, OBEJERO-PAZ CA, ZHAO S, BROWN AM: The binding site for channel blockers that rescue misprocessed human long QT syndrome Type 2 ether-a-gogo-relared gene (HERG) mutations. J. Biol. Chem. (2002) 277(7):4989-4998.
124. DELISLE BP, ANDERSON CL, BALIJEPALLI RC et al.: Thapsigargin selectively rescues the trafficking-defective LQT2 channels G601S and F805C. J. Biol. Chem. (2003) 278(37):35749-54357.
125. + channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation (2002) 105(24):2830-2835.
126. FICKER E, DENNIS AT, WANG L, BROWN AM: Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ. Res. (2003) 92(12):e87-e100.
127. v.11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation (2006) 113(3):365-373.
128. HOLLON T: Researchers and regulators reflect on first gene therapy death. Nat. Med. (2000) 6(1):6.
129. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol. Pharm. (1998) 54(4):695-703.
130. + channel. J. Mol. Cell Cardiol. (2006) 40(1):107-118.
131. WITCHEL HJ, PABBATHI VK, HOFMANN G, PAUL AA, HANCOX JC: Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. (2002) 512(1-3):59-66.
132. PACHER P, BAGI Z, LAKO-FUTO Z et al.: Cardiac electrophysiological effects of citalopram in guinea pig papillary muscle comparison with clomipramine. Gen. Pharmacol. (2000) 34(1):17-23.
133. CARLSSON L: In vitro and in vivo models for testing arrhythmogenesis in drugs. J. Intern. Med. (2006) 259(1):70-80.
134. CARLSSON L, ABRAHAMSSON C, ANDERSSON B, DUKER G, SCHILLER-LINHARDT G: Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc. Res. (1993) 27(12):2186-2193.
135. HONDEGHEM LM: TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability). Novartis Found. Symp. (2005) 266:235-244.
136. HONDEGHEM LM, DUJARDIN K, DE CLERCK F: Phase II prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. (2001) 50(2):345-353.
137. TESTAI L, CALDERONE V, SALVADORI A et al.: QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. J. Appl. Toxicol. (2004) 24(3):217-222.
138. LANGHEINRICH U, VACUN G, WAGNER T: Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. (2003) 193(3):370-382.
139. JAMIESON C, MOIR EM, RANKOVIC Z, WISHART G: Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. (2006) 49(17):5029-5046.
140. ZHU BY, JIA ZJ, ZHANG P et al.: Inhibitory effect of carboxylic acid group on hERG binding. Bioorg. Med. Chem. Lett. (2006) 16(21):5507-5512.
141. + channel: progress in understanding the molecular basis of its unusual gating kinetics. Eur. Biophys. J. (2004) 33(2):89-97.
142. RODEN DM: Pharmacogenetics and drug-induced arrhythmias. Cardiovasc. Res. (2001) 50(2):224-231.
143. WALKER BD, KRAHN AD, KLEIN GJ et al.: Congenital and acquired long QT syndromes. Can. J. Cardiol. (2003) 19(1):76-87.
144. PUDDU PE, CRINITI A, MONTI F: Screening for drug-induced (acquired) long QT syndrome: is it time to apply new methods? Eur. Heart J. (2001) 22(5):363-369.
145. PAULUSSEN AD, GILISSEN RA, ARMSTRONG M et al.: Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. (2004) 82(3):182-188.